GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
Currently predicting for Fri, 19 Apr 2024

ARQL Predictions History

4 years ago
JS predicted that ARQL for 2019-10-23 is going $9.61 (7.86%)

4 years ago
Alan predicted that ARQL for 2019-10-23 is going $9.31 (4.49%)

4 years ago
GoldenNugget predicted that ARQL for 2019-05-07 is going $6.47 (1.79%)

4 years ago
joe1234 predicted that ARQL for 2019-05-06 is going $6.60 (1.38%)

4 years ago
GoldenNugget predicted that ARQL for 2019-05-06 is going $6.31 (-3.00%)

4 years ago
GoldenNugget predicted that ARQL for 2019-05-03 is going $6.42 (2.22%)

4 years ago
PumpTheseNumbers predicted that ARQL for 2019-05-02 is going $6.42 (2.23%)

4 years ago
NameNotImportant predicted that ARQL for 2019-04-24 is going $6.38 (0.47%)

4 years ago
NameNotImportant predicted that ARQL for 2019-04-23 is going $6.25 (-4.43%)

5 years ago
JS predicted that ARQL for 2019-04-08 is going $5.14 (0.59%)

Click to get the best stock tips daily for free!

About ArQule

ArQule ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesotheli... ARQL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT